补肺汤治疗特发性肺间质纤维化患者临床效果观察OA

Objective To analyze the effects of Bufei Decoction(补肺汤)on inflammation factors,regulatory factors,lactate dehydrogenase(LDH),activating transcription factor 4(ATF4)and prognosis in patients with idiopathic pulmonary fibrosis(IPF).Methods A total of 90 IPF patients admitted to the hospital from January 2024 to December 2024 were randomly divided into a study group and a control group,with 45 patients in each group.The control group received conventional treatment,while the study group additionally received Bufei Decoction.The efficacy,pulmonary function indicators,serum inflammation factors,regula-tory factors,incidence of adverse reactions and chest high resolution CT(HRCT)scores were compared between the two groups.Results The total effective rate in the study group after treatment was 91.11%(41/45),higher than that(75.56%,34/45)in the control group(P＜0.05).After treatment,the levels of(peripheral capillary oxygen saturation(SpO2),partial pressure of oxygen in arterial blood(PaO2),diffusing capacity of the lungs for carbon monoxide(DLCO)and forced vital capacity(FVC)significant-ly improved in both groups(P＜0.05).Serum levels of LDH,ALP,transforming growth factor-β(TGF-β),ATF4,interleukin-6(IL-6),interleukin-1β(IL-1β)and tumor necrosis factor-α(TNF-α)decreased compared to those before treatment,with the levels in the study group being significantly lower than those in the control group(P＜0.05).The expression rates of Snail1 and Zeb1 in the study group were both lower than those in the control group,while the expression rate of PHD2 was higher than that in the control group(P＜0.05).The incidence of adverse reactions in the study group was 6.67%(3/45),lower than that(26.67%,12/45)in the control group(P＜0.05).Chest HRCT scores post-treatment were lower than pre-treatment scores in both groups(P＜0.05),with the study group having lower scores compared to the control group(P＜0.05).Conclusion The ad-dition of Bufei Decoction to the treatment of IPF significantly improves the clinical efficacy,pulmonary function and inflammatory response,while reducing the incidence of adverse outcomes.